Skip to main content
. 2021 Feb 1;9:e10280. doi: 10.7717/peerj.10280

Figure 3. GHSROS mediates cell survival and resistance to the cytotoxic drug docetaxel.

Figure 3

(A) Viability of GHSROS-overexpressing LNCaP cells under different culture conditions. Cell number was assessed using WST-1. Cells were treated with enzalutamide (ENZ; 10 µM) or docetaxel (DTX; 5 nM) for 96 h and grown in either 2% FBS or 5% charcoal stripped serum (CSS) RPMI-1640 media (n = 3). Mean ±   s.e.m. *P ≤ 0.05, ***P ≤ 0.001, Student’s t-test. (B) GHSROS expression of native PC3 and LNCaP cells treated with docetaxel. Cells were grown in RPMI-1640 media with 2% FBS and treated with 1–20 nM docetaxel (DTX) for 48 h (n = 3). Fold-enrichment of GHSROS normalized to RPL32 and compared to empty vector control. Parameters and annotations as in (A). (C) GHSROS and PSA (KLK3) expression of native LNCaP cells treated with ENZ (10 µM in 2% FBS or 5% CSS RPMI-1640) or DTX (5 nM in 2% FBS RPMI-1640) for 48 h (n = 3). Parameters and annotations as in (A).